Thinking Disorders
Thinking disorders is a non-formal umbrella term for conditions involving disturbances in thought content (delusions), thought process (formal thought disorder), or perception (hallucinations). The DSM-5-TR addresses these features in Schizophrenia Spectrum and Other Psychotic Disorders.
Overview
“Thinking disorders” is a non-formal lay umbrella term for conditions involving disturbances in thought content, thought process, or perception. The closest formal correspondence is the DSM-5-TR chapter Schizophrenia Spectrum and Other Psychotic Disorders, which includes schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, schizotypal personality disorder, substance/medication-induced psychotic disorder, psychotic disorder due to another medical condition, catatonia, and other related conditions.
These disorders share characteristic disturbances across five symptom domains: positive symptoms (delusions, hallucinations, formal thought disorder), negative symptoms (diminished emotional expression, avolition), cognitive symptoms (impaired attention, working memory, executive function), disorganized symptoms (disorganized speech and behaviour), and affective symptoms (depression, anxiety often present).
Lifetime prevalence of schizophrenia is approximately 0.7-1% globally. Other psychotic disorders are less common individually but collectively affect approximately 3% of the population at some point. Onset is typically late adolescence or early adulthood, with men presenting earlier (mean ~18-25) than women (mean ~25-35). A second smaller peak of onset occurs in mid-to-late life, particularly in women.
Schizophrenia spectrum disorders involve documented neurobiological changes in brain structure and function, with the strongest evidence base for any “biological” psychiatric disorder. Genetic heritability is approximately 70-80%. Despite the biological basis, psychosocial factors (stress, trauma, social adversity, substance use — particularly cannabis) influence onset, course, and outcome.
Effective treatment substantially improves outcomes. Antipsychotic medication is the foundation; coordinated specialty care for first-episode psychosis (combining medication, psychotherapy, family education, supported employment, and case management) substantially outperforms standard care. Many people with schizophrenia achieve sustained recovery and meaningful life roles with comprehensive treatment.
Signs and symptoms
- Delusions — Fixed false beliefs not amenable to change despite contradicting evidence — persecutory, grandiose, religious, somatic, referential, or other content.
- Hallucinations — Sensory experiences without external source — most commonly auditory (voices), but may include visual, olfactory, gustatory, or tactile.
- Disorganized thinking and speech — Formal thought disorder — derailment, tangentiality, illogical or incomprehensible speech.
- Grossly disorganized or abnormal motor behaviour — Including catatonia (immobility, mutism, posturing) at one extreme or unpredictable agitation at the other.
- Negative symptoms — Diminished emotional expression, avolition (decreased motivation), alogia (reduced speech), anhedonia, asociality.
- Cognitive impairment — Difficulties with attention, working memory, processing speed, and executive function — present from early in illness, often persistent.
- Social withdrawal — Reduction in social engagement, often beginning in prodrome before frank psychotic symptoms emerge.
- Functional decline — Significant decline in academic, occupational, social, or self-care functioning, often gradual over months to years before diagnosis.
- Suspiciousness or paranoia — Increased mistrust, scanning for threat, sense of being targeted or watched.
- Suicide risk — Approximately 5-10% of individuals with schizophrenia die by suicide; risk is highest in young men early in illness, during depressive episodes, and following hospital discharge.
Diagnostic context
The DSM-5-TR Schizophrenia Spectrum and Other Psychotic Disorders chapter includes:
Schizophrenia (295.90): 2+ of (delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behaviour, negative symptoms) for ≥1 month (active phase), with at least one being delusions, hallucinations, or disorganized speech; significant functional impairment; continuous signs of disturbance for ≥6 months total; not better explained by schizoaffective, mood, substance, or medical condition.
Schizoaffective Disorder (295.70): uninterrupted period of mood episode (depressive or manic) concurrent with Criterion A of schizophrenia; delusions or hallucinations for ≥2 weeks in the absence of mood episode; mood episode symptoms present majority of total active and residual periods.
Schizophreniform Disorder (295.40): like schizophrenia but episode lasts 1-6 months.
Brief Psychotic Disorder (298.8): psychotic symptoms lasting 1 day to 1 month with full return to premorbid functioning.
Delusional Disorder (297.1): 1+ delusions for ≥1 month, no other Criterion A symptoms of schizophrenia, functioning not markedly impaired.
Substance/Medication-Induced Psychotic Disorder (292.9): psychotic symptoms attributable to substance or medication.
Differential diagnosis includes mood disorder with psychotic features (mood-congruent or mood-incongruent), substance-induced psychosis (cannabis, stimulants, hallucinogens, alcohol withdrawal), psychosis due to medical condition (epilepsy, brain tumor, autoimmune encephalitis, dementia), and PTSD with dissociative or auditory experiences. Comprehensive medical evaluation including neuroimaging is appropriate for first-episode psychosis.
Causes and risk factors
Schizophrenia spectrum disorders develop through interaction of strong genetic and neurobiological vulnerabilities with environmental triggers:
Genetic factors: heritability ~70-80% — among the highest of any psychiatric disorder. First-degree relatives of individuals with schizophrenia have ~10x increased risk. Multiple common variants of small effect plus rare copy-number variants of larger effect contribute.
Neurobiological factors: dopaminergic dysregulation (hyperactive mesolimbic, hypoactive prefrontal), glutamatergic abnormalities, GABA disturbances, neurodevelopmental anomalies (gray matter loss, ventricular enlargement), inflammation, and altered functional connectivity.
Prenatal and perinatal factors: maternal infection during pregnancy, obstetric complications, prenatal nutritional deficiencies (vitamin D), and birth season (slight excess in late winter/early spring births in northern hemisphere).
Childhood and adolescent factors: trauma exposure, childhood adversity, urbanicity, migration (particularly second-generation immigrants), and minority status.
Substance factors: cannabis use is a robust environmental risk factor; high-potency cannabis substantially elevates risk, particularly with adolescent initiation. Stimulants, hallucinogens, and other substances can precipitate psychotic episodes.
Stress factors: major life stressors and high-expressed-emotion family environments are associated with relapse and onset.
Comorbidity: depression, anxiety, substance use disorders, and metabolic syndrome (often medication-related) are commonly comorbid. Suicide risk is substantially elevated.
Typical treatments
Comprehensive evidence-based treatment includes:
Antipsychotic medication: foundation of treatment. Second-generation (atypical) antipsychotics — risperidone, olanzapine, quetiapine, aripiprazole, paliperidone, lurasidone, others — are first-line. Long-acting injectable formulations substantially improve adherence. Clozapine is the most effective agent for treatment-resistant schizophrenia and has unique anti-suicide effects, but requires hematological monitoring due to agranulocytosis risk.
Coordinated Specialty Care for First-Episode Psychosis: integrated team-based approach combining medication, individual therapy, family psychoeducation, supported employment/education, and case management. Substantially better outcomes than standard care; international standard for first-episode care.
Cognitive behavioural Therapy for Psychosis (CBTp): structured CBT addressing distress related to psychotic experiences, coping strategies, and recovery goals. Strong evidence base.
Family Psychoeducation and Family-Focused Therapy: reduce relapse and improve outcomes; included in CSC models.
Cognitive Remediation: structured cognitive-skills training for the cognitive impairments characteristic of schizophrenia.
Social Skills Training for the negative-symptom and social-functioning dimensions.
Supported Employment (Individual Placement and Support model) — strongest evidence-base of any vocational intervention.
Assertive Community Treatment (ACT): intensive multidisciplinary outpatient model for severe presentations; reduces hospitalization and improves community functioning.
Treatment of comorbid conditions: depression, substance use disorders, metabolic complications all warrant attention.
Crisis intervention and hospitalization when safety requires.
Recovery-oriented care: emphasizes meaningful life roles, self-determination, peer support, and recovery beyond symptom remission.
When to seek help
Professional evaluation is indicated when:
- You or a family member is experiencing changes in thinking, perception, or behaviour — particularly hearing voices, holding unusual beliefs, or significant social withdrawal.
- You are noticing prodromal changes in a young person — declining school performance, social withdrawal, unusual ideas, suspiciousness, or magical thinking.
- You are experiencing first-episode psychotic symptoms — early intervention substantially improves long-term outcomes.
- You have a known psychotic disorder and are experiencing relapse or worsening.
- Cannabis or other substance use has triggered psychotic experiences.
- You are experiencing depression, suicidal ideation, or substance use complications alongside thinking disorder symptoms.
If you or a family member is experiencing acute psychosis with safety concerns (severe agitation, threats to self or others, command hallucinations to harm), contact emergency services or local mental health crisis line. 9-8-8 (Suicide Crisis Helpline, 24/7), 1-833-456-4566 (Talk Suicide Canada). Provincial psychiatric crisis services and Mobile Crisis Teams provide community-based assessment.
For first-episode psychosis specifically, request referral to a Coordinated Specialty Care program — these programs exist in many Canadian provinces (e.g., Early Psychosis Program in Alberta, First Episode Psychosis Programs across Canada) and substantially improve long-term outcomes when accessed early.
Frequently asked questions
What is psychosis?
Is schizophrenia split personality?
Can people with schizophrenia recover?
Is cannabis safe with a psychotic illness?
Is medication necessary forever?
How do I help a family member with psychosis?
References
- American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). APA.
- Kahn, R. S., et al. (2015). Schizophrenia. Nature Reviews Disease Primers, 1, 15067.
- Kane, J. M., et al. (2016). Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE Early Treatment Program. American Journal of Psychiatry, 173(4), 362–372.
- Marder, S. R., & Cannon, T. D. (2019). Schizophrenia. New England Journal of Medicine, 381(18), 1753–1761.
- Canadian Psychiatric Association. (2017). Clinical Practice Guidelines for the Management of Schizophrenia.
Find the pattern behind what's been feeling hard
A few simple questions to help surface the concerns that may fit best.
Find Your PatternFind a Therapist by City
Browse therapy availability by city to see local and virtual options, explore services, and connect with a clinician who can serve your area.
Find a Therapist by Province
Browse therapy options by province to see which clinicians are available to work with clients in your region.
Trusted by Leading Psychology & Mental Health Organizations Across Canada
ShiftGrit Psychology & Counselling is professionally regulated, certified, and recognized by leading psychology and mental-health organizations across Canada. These associations reflect our commitment to ethical practice, clinical standards, and evidence-informed therapy through Identity-Level Therapy and Reconditioning.
Trusted By Alberta’s Leading Psychology & Mental Health Organizations
ShiftGrit Psychology & Counselling is professionally regulated, certified, and recognized by leading psychology and mental-health organizations across Alberta and Canada. These associations reflect our commitment to ethical practice, clinical standards, and evidence-informed therapy through Identity-Level Therapy and Reconditioning.
Regulated and affiliated across Alberta’s leading psychology, counselling, and mental-health organizations.
Regulated and affiliated across Canada’s leading psychology, counselling, and mental-health organizations.
